Amalgamated Bank Buys 1,932 Shares of Kenvue Inc. (NYSE:KVUE)

Amalgamated Bank boosted its stake in Kenvue Inc. (NYSE:KVUE) by 0.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 378,249 shares of the company’s stock after purchasing an additional 1,932 shares during the quarter. Amalgamated Bank’s holdings in Kenvue were worth $8,076,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of KVUE. Alerus Financial NA raised its position in shares of Kenvue by 0.3% in the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after buying an additional 491 shares in the last quarter. Kiley Juergens Wealth Management LLC raised its position in Kenvue by 1.9% during the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock valued at $579,000 after purchasing an additional 500 shares in the last quarter. Principle Wealth Partners LLC lifted its stake in Kenvue by 3.7% during the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after purchasing an additional 500 shares during the last quarter. White Pine Capital LLC boosted its holdings in shares of Kenvue by 1.0% in the 4th quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock valued at $1,165,000 after purchasing an additional 542 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators boosted its holdings in shares of Kenvue by 29.0% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock valued at $54,000 after purchasing an additional 568 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

KVUE has been the subject of a number of research analyst reports. Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. Canaccord Genuity Group lowered their target price on Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Piper Sandler raised their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday. Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Finally, Barclays dropped their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $23.08.

Kenvue Price Performance

KVUE stock opened at $23.22 on Thursday. The company has a market capitalization of $44.52 billion, a P/E ratio of 43.81, a PEG ratio of 2.62 and a beta of 1.45. The company has a fifty day moving average price of $21.36 and a 200-day moving average price of $22.23. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.53%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.